Vanda’s social anxiety drug flunks Phase 3 trial in female patients

Vanda Pharmaceuticals halts social anxiety drug program after Phase 3 failure

Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.